Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 2-[(4-isothiocyanatophenyl)methyl]-
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

Henan Tianfu Chemical Co., Ltd.
China
Product Name: 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

127985-74-4

127985-74-4 structure

Name: p-SCN-Bn-DOTA
Chemical Name: 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
CAS Number: 127985-74-4
Molecular Formula: C₂₄H₃₃N₅O₈S
Molecular Weight: 551.61
Catalog: Research Areas Cancer
Create Date: 2018-11-25 14:31:37
Modify Date: 2024-01-07 17:35:14
p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunotherapy of tumor[1][2].

Name	2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Synonyms	UNII-13KT123BYW 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid cDOTA-Bnz-NCS p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,2-((4-isothiocyanatophenyl)methyl) 2-(p-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraaceticacid p-SCN-Bz-DOTA p-SCN-Bn-DOTA 2-(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

Description	p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunotherapy of tumor[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	p-SCN-Bn-DOTA is complexed with 5 different metal ions: In(III), Y(III), Lu(III), Gd(III) and Cu(II)[2].
References	[1]. Vera DRB, et, al. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 2011 Jun;26(3):287-97. [2]. Giannini G, et, al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253.